Next Article in Journal
Topsensterols A–C, Cytotoxic Polyhydroxylated Sterol Derivatives from a Marine Sponge Topsentia sp.
Next Article in Special Issue
Molecular Weight-Dependent Immunostimulative Activity of Low Molecular Weight Chitosan via Regulating NF-κB and AP-1 Signaling Pathways in RAW264.7 Macrophages
Previous Article in Journal
High-EPA Biomass from Nannochloropsis salina Cultivated in a Flat-Panel Photo-Bioreactor on a Process Water-Enriched Growth Medium
Previous Article in Special Issue
Anticancer Effect of Fucoidan on DU-145 Prostate Cancer Cells through Inhibition of PI3K/Akt and MAPK Pathway Expression
Article Menu

Export Article

Open AccessReview
Mar. Drugs 2016, 14(8), 145; doi:10.3390/md14080145

Fucoidans in Nanomedicine

1
Inserm, U1148, LVTS, University Paris Diderot, X Bichat Hospital, F-75877 Paris, France
2
Galilée Institute, University Paris 13, Sorbonne Paris Cité, F-93430 Villetaneuse, France
3
Algues & Mer, Kernigou, F-29242 Ouessant, France
These authors contributed equally to this work.
*
Author to whom correspondence should be addressed.
Academic Editor: Paola Laurienzo
Received: 17 June 2016 / Revised: 20 July 2016 / Accepted: 21 July 2016 / Published: 29 July 2016
(This article belongs to the Collection Marine Polysaccharides)
View Full-Text   |   Download PDF [806 KB, uploaded 29 July 2016]   |  

Abstract

Fucoidans are widespread cost-effective sulfated marine polysaccharides which have raised interest in the scientific community over last decades for their wide spectrum of bioactivities. Unsurprisingly, nanomedicine has grasped these compounds to develop innovative therapeutic and diagnostic nanosystems. The applications of fucoidans in nanomedicine as imaging agents, drug carriers or for their intrinsic properties are reviewed here after a short presentation of the main structural data and biological properties of fucoidans. The origin and the physicochemical specifications of fucoidans are summarized in order to discuss the strategy of fucoidan-containing nanosystems in Human health. Currently, there is a need for reproducible, well characterized fucoidan fractions to ensure significant progress. View Full-Text
Keywords: fucoidans; nanomedicine; sulfated polysaccharides; nanosystems; drug delivery; imaging agent; tissue regeneration fucoidans; nanomedicine; sulfated polysaccharides; nanosystems; drug delivery; imaging agent; tissue regeneration
Figures

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Chollet, L.; Saboural, P.; Chauvierre, C.; Villemin, J.-N.; Letourneur, D.; Chaubet, F. Fucoidans in Nanomedicine. Mar. Drugs 2016, 14, 145.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Mar. Drugs EISSN 1660-3397 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top